Literature DB >> 4525428

Survival of human sickle-cell erythrocytes in heterologous species: response to variations in oxygen tension.

O Castro, J Orlin, M W Rosen, S C Finch.   

Abstract

Survival characteristics, after transfusion, of erythrocytes from patients with homozygous sickle-cell disease were studied in rats. The study was made possible by previous injection of the animals with ethyl plamitate, which depressed reticuloendothelial system function, and with a factor in cobra venom that inactivated complement. This treatment prevented the rapid phagocytosis and intravascular hemolysis of donor erythrocytes that usually follow a heterologous transfusion. Both immediate after transfusion recovery and survival of (51)Cr-labeled sickle erythrocytes were decreased in comparison to the values obtained for control erythrocytes from individuals without sickle-cell anemia. Survival of sickle erythrocytes was improved during exposure of the animals to 100% O(2). Hypoxia (7-10% O(2)) resulted in the abrupt removal of 35-60% of sickle erythrocytes from the rats' circulation. Variations in oxygen tension did not affect survival of control erythrocytes. The usefulness of this convenient animal model for the study of sickle-cell anemia is suggested by the similarities between our results and the behavior of sickle erythrocytes in humans. The system may also be suitable for studying a wide variety of other human erythrocyte disorders.

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4525428      PMCID: PMC433734          DOI: 10.1073/pnas.70.8.2356

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  5 in total

1.  Blood and packed cell volume of the adult rat as measured by tagged cells.

Authors:  L M SHARPE; G G CULBRETH; J R KLEIN
Journal:  Proc Soc Exp Biol Med       Date:  1950-08

2.  Pathophysiologic aspects of sickle cell anemia.

Authors:  C A Finch
Journal:  Am J Med       Date:  1972-07       Impact factor: 4.965

3.  Study of the mechanism of ethyl palmitate-induced splenic destruction.

Authors:  S Kawasaki; S C Finch
Journal:  J Reticuloendothel Soc       Date:  1972-06

4.  A new concept of immunosuppression in hypersensitivity reactions and in transplantation immunity.

Authors:  R A Nelson
Journal:  Surv Ophthalmol       Date:  1966-08       Impact factor: 6.048

5.  The effects of a cobra venom factor and ethyl palmitate on the prolongation of survival of heterologous erythrocytes.

Authors:  M C Wright; R A Nelson; S C Finch
Journal:  Yale J Biol Med       Date:  1970-12
  5 in total
  7 in total

1.  An alternative decomplementation method for the measurement of the survival of human erythrocytes transfused into rats.

Authors:  F F Costa; M A Zago; C Bottura
Journal:  Experientia       Date:  1981-04-15

2.  In vivo blood flow abnormalities in the transgenic knockout sickle cell mouse.

Authors:  S H Embury; N Mohandas; C Paszty; P Cooper; A T Cheung
Journal:  J Clin Invest       Date:  1999-03       Impact factor: 14.808

3.  Survival of human 51Cr erythrocytes in guinea-pigs.

Authors:  A N Azikiwe; O Castro; G W Obaldiston; S C Finch
Journal:  Br J Exp Pathol       Date:  1978-06

Review 4.  Transgenic animal models of sickle cell disease.

Authors:  M E Fabry
Journal:  Experientia       Date:  1993-01-15

5.  The effect of hemoglobin carbamylation on the survival of human sickle cell erythrocytes in rats.

Authors:  O Castro; J Orlin; S C Finch
Journal:  Yale J Biol Med       Date:  1974-03

6.  Expanded operational concept of high risk groups and its role in standard setting.

Authors:  E J Calabrese
Journal:  Environ Health Perspect       Date:  1983-10       Impact factor: 9.031

7.  New strategies to prolong the in vivo life span of iron-based contrast agents for MRI.

Authors:  Antonella Antonelli; Carla Sfara; Serafina Battistelli; Barbara Canonico; Marcella Arcangeletti; Elisabetta Manuali; Sonia Salamida; Stefano Papa; Mauro Magnani
Journal:  PLoS One       Date:  2013-10-25       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.